Lymphoblastic Lymphoma, Childhood, Lymphoma, Non-Hodgkin, NOTCH1 Gene Mutation, Pediatric Cancer, PTEN Loss
Conditions
Brief summary
With the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-Hodgkin lymphoma (NHL) in children. In recent years, the criteria for clinical staging and efficacy evaluation of NHL in children have been updated. Recent clinical studies of COG in the United States and LMB in France have confirmed that molecular biological markers such as Notch1, PTEN and LOH6q are significantly associated with the prognosis of T-lymphoblastic lymphoma (T-LBL). These molecular biological markers should be included in the new risk stratification system. High-intensity treatment of high-risk patients will improve survival. Recent studies have also suggested that PET/CT is helpful in evaluating residual lesions in patients with lymphoma after chemotherapy. In order to keep pace with the times in the diagnosis, clinical staging, risk stratification, efficacy evaluation and treatment of NHL in children. SCCCG-LBL-2017 was formulated by South China Children's Cancer Group of Non-Hodgkin lymphoma, which mainly updated in clinical staging, efficacy evaluation, risk stratification, treatment,etc..
Detailed description
Research purpose: 1. To investigate the efficacy and safety of SCCCG-LBL-2017 in Chinese children with LBL. 2. To explore the feasibility of risk stratification of T-LBL by combining genotyping. 3. To investigate the correlation between MDD and MRD in lymphoblastic lymphoma and prognosis. 4. To investigate the role of PET/CT in the assessment of residual lymphoblastic lymphoma. 5. To explore the effect of reducing HD-MTX dosage and shortening maintenance therapy time on the efficacy and survival of low-risk LBL patients. 6. To explore the effect of prolonging the duration of maintenance therapy on the efficacy and survival of high-risk LBL patients.
Interventions
None listed
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Age \< 18 years old 2. Pathologically confirmed lymphoblastic lymphoma 3. Newly diagnosed patients 4. Informed consent of guardian of children patients -
Exclusion criteria
1. Age \> 18 years old 2. Recurrent lymphoblastic lymphoma 3. Secondary immunodeficiency.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival (EFS) | through study completion, maximal eight years | EFS is defined as time from start of treatment/randomization up to event or to date of last contact for patients without event. The following occurrences are defined as an event: non-response, progressive disease or relapse, treatment related death, death of any other cause or diagnosis of secondary malignancies. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | through study completion, maximal eight years | OS is defined as time from start of treatment/randomization up to death of any |
| Relapse-free survival (RFS) | through study completion, maximal eight years | RFS is defined as time from start of treatment/randomization up to event or to date of last contact for patients without event. The following occurrences are defined as an event: non-response, progressive disease, or relapse. |
| Response rate (RR) | on an average 3 weeks after finish of treatment | Complete response, partial remission, objective effect, stable disease or progressive disease |
| Adverse event rate | through study completion, maximal eight years | Rate of patients with acute toxicity defined as grade III/IV/V AE |
Countries
China
Contacts
Primary ContactZhen zijun
Backup ContactSun xiaofei
Outcome results
None listed